|
Market Closed -
Sao Paulo
15:45:54 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 136.35 BRL | -4.23% |
|
-5.40% | -19.16% |
| 10-02 | AbbVie joins US government pilot to test drug discount rebates | RE |
| 10-02 | Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion | DJ |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 243,576 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -15.37% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 263,270 | 255,506 | 246,763 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -15.4% | -2.95% | -3.42% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20x | 17.5x | 15.1x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.51x | 3.94x | 3.41x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1x | 1.2x | 1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.86x | 3.64x | 3.42x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.17x | 3.81x | 3.47x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 11.9x | 10.5x | 9.2x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.5x | 11x | 9.66x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 27.4x | 19.6x | 16.9x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.64% | 5.09% | 5.93% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.34 | 3.544 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.13% | 2.26% | 2.33% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.844 | 8.987 | 10.37 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.6% | 39.4% | 35.2% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,172 | 67,008 | 71,142 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,193 | 24,358 | 26,836 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,100 | 23,268 | 25,545 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,044 | 13,773 | 15,801 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,694 | 11,931 | 3,188 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 157.04 | 157.04 | 157.04 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 410.8B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- A1ZN34 Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
